Chiudi

Aggiungi l'articolo in

Chiudi
Aggiunto

L’articolo è stato aggiunto alla lista dei desideri

Chiudi

Crea nuova lista

Inflammatory Mechanisms in Mediating Hearing Loss - cover
Inflammatory Mechanisms in Mediating Hearing Loss - cover
Dati e Statistiche
Wishlist Salvato in 0 liste dei desideri
Inflammatory Mechanisms in Mediating Hearing Loss
Disponibilità in 2 settimane
130,70 €
130,70 €
Disponibilità in 2 settimane
Chiudi

Altre offerte vendute e spedite dai nostri venditori

Altri venditori
Prezzo e spese di spedizione
ibs
Spedizione Gratis
130,70 €
Vai alla scheda completa
Altri venditori
Prezzo e spese di spedizione
ibs
Spedizione Gratis
130,70 €
Vai alla scheda completa
Altri venditori
Prezzo e spese di spedizione
Chiudi
ibs
Chiudi

Tutti i formati ed edizioni

Chiudi
Inflammatory Mechanisms in Mediating Hearing Loss - cover

Descrizione


Common forms of preventable hearing loss are drug and noise-induced hearing loss which are believed to be produced by a similar mechanism. The generation of reactive oxygen species appears to be a common mechanism mediating hearing loss produced by these different sources.  As such, a number of laboratories have focused their research towards identifying the sources of ROS production in the cochlea following administration of chemotherapeutic agents or noise exposure. This led to the identification of ROS generating enzymes, such as xanthine oxidases, nitric oxide synthase, and NADPH oxidases which are activated and/or induced during the development of hearing loss. A consequence of these findings was the implementation of antioxidants in preclinical studies for the treatment of hearing loss. These antioxidants have provided different levels of protection in animal and human studies, but none of these have been approved by the US Food and Drug Administration for the treatmentof hearing loss. More recently, it was shown that noise-induced hearing loss was associated with recruitment of inflammatory cells and mediators in the cochlea. This finding would suggest that noise could produce injury to the cochlea which stimulates local and/or circulating inflammatory cells. A similar finding was observed in the cochlea following administration of the anticancer drug, cisplatin. In addition, our laboratory and others have provided a plausible mechanism by which noise or chemotherapeutic agents could stimulate the inflammatory response. Surprisingly, this mechanism involves ROS activation of transcription factors linked to inflammatory processes in the cochlea. These studies have led to the use of anti-inflammatory agents for the treatment of hearing loss. Preliminary studies targeting inflammatory cytokines appear especially promising in preclinical studies.  A primary goal of this project is to describe our current understanding of theoxidant hypothesis of noise and drug-induced hearing loss and show how this relates to cochlear inflammation. Several different aspects of the cochlear inflammatory process will be discussed in detail, ranging from the sources of inflammatory cells, chemokines, inflammatory cytokines, and cochlea resident immune cells. Molecular pathways leading to activation of the local inflammatory process will be highlighted and treatment options will be discussed. The relevance of certain clinically used anti-inflammatory interventions, such as trans-typmanic steroids will also be discussed. Furthermore, we will examine recent patents focusing on the use of anti-inflammatory agents for the treatment of drug and noise-induced hearing loss.
Leggi di più Leggi di meno

Dettagli

2018
Hardback
231 p.
Testo in English
235 x 155 mm
9783319925066
Chiudi
Aggiunto

L'articolo è stato aggiunto al carrello

Informazioni e Contatti sulla Sicurezza dei Prodotti

Le schede prodotto sono aggiornate in conformità al Regolamento UE 988/2023. Laddove ci fossero taluni dati non disponibili per ragioni indipendenti da IBS, vi informiamo che stiamo compiendo ogni ragionevole sforzo per inserirli. Vi invitiamo a controllare periodicamente il sito www.ibs.it per eventuali novità e aggiornamenti.
Per le vendite di prodotti da terze parti, ciascun venditore si assume la piena e diretta responsabilità per la commercializzazione del prodotto e per la sua conformità al Regolamento UE 988/2023, nonché alle normative nazionali ed europee vigenti.

Per informazioni sulla sicurezza dei prodotti, contattare productsafetyibs@feltrinelli.it

Chiudi

Aggiungi l'articolo in

Chiudi
Aggiunto

L’articolo è stato aggiunto alla lista dei desideri

Chiudi

Crea nuova lista

Chiudi

Chiudi

Siamo spiacenti si è verificato un errore imprevisto, la preghiamo di riprovare.

Chiudi

Verrai avvisato via email sulle novità di Nome Autore